Bellerophon Therapeutics recently offered an update on the company’s INOpulse system, as part of its first quarter 2017 financial report. The system is in clinical testing as a therapy for three types of pulmonary hypertension. The Phase 3 INOpulse program for pulmonary arterial hypertension (PAH) has been modified to speed up its clinical development.
News
Patient enrollment is complete in a Phase 2 clinical trial of ubenimex as an add-on to standard therapy for pulmonary arterial hypertension (PAH), according to ubenimex’s developer, Eiger BioPharmaceuticals. Sixty-one patients at 45 sites in the United States and Canada have been enrolled in the LIBERTY trial (NCT02664558). The randomized, double-blind,…
Reata Pharmaceuticals is enrolling participants for two ongoing clinical trials of bardoxolone methyl as a treatment for pulmonary arterial hypertension (PAH) and pulmonary hypertension (PH) caused by an underlying interstitial lung disease. Bardoxolone methyl belongs to a class of small molecules that target an important transcription factor called Nrf2.
Lung disease is one of the main causes of American deaths, second only to heart disease. While some lung diseases are genetic and unavoidable, following a healthy lifestyle and avoiding lung irritants can help protect you from developing many of them. We’ve put together a list of tips to help lower your risk of developing a…
Pulmonary hypertension (PH) only rarely affects children born with the genetic condition incontinentia pigmenti, illustrating that researchers lack insights into how molecular abnormalities translate into problems in the heart and lungs. A case report by researchers from Saudi Arabia’s King Abdullah International Medical Research Center in Riyadh illustrates the condition, and…
Third Pole has won a Johnson & Johnson Innovation award for a lighter device that provides an unlimited supply of nitric oxide (NO) to patients with pulmonary hypertension (PH) and other respiratory conditions. The beauty of Third Pole’s Electric NO device, which won Johnson Innovation’s JLABS @ M2D2 QuickFire Challenge,…
The new pulmonary endarterectomy (PEA) surgery simulator — a 3D device developed by the National Research Council of Canada with support from Bayer — could potentially improve the lives of thousands of Canadians with chronic thromboembolic pulmonary hypertension (CTEPH). The first-of-its-kind simulator will allow surgeons to train more efficiently for surgery to treat CTEPH, a…
Eiger BioPharmaceuticals will host a lunch May 10 in New York City to discuss the need for potential new mechanisms to treat pulmonary arterial hypertension (PAH). The event, to take place at the Lotte New York Palace Hotel, includes presentations by Stanford University’s Dr. Mark Nicolls and Dr. Roham Zamanian. Both…
Germany’s enmodes won recognition at the recent 2017 Design of Medical Devices Conference in Minneapolis for its RAS-Q technology to help people with pulmonary hypertension (PH). RAS-Q is a respiratory assist device that offers comprehensive, fully portable, cost-effective and protective treatment for PH patients. One week before the April 9-12 conference where RAS-Q won an Emerging…
Movie-goers will be seeing pulmonary hypertension public service announcements at selected theaters in California, Nevada and Washington, beginning today, which is World PH Day. The Phaware Global Association and On the Wall Theater Advertising arranged for the I’m Aware That I’m Rare PSAs to run in 80 Galaxy theaters and IMAX…
SteadyMed announced  it has received a U.S. patent for its PatchPump infusion system for injectable drugs, including Trevyent, the company’s lead candidate as a potential treatment for pulmonary arterial hypertension (PAH). The patent, issued by the U.S. Patent and Trademark Office (No. 14/384,152), includes but is not limited to claims for a pump…
The INOpulse nitric-oxide dispenser improves respiratory and exercise capacity in patients with difficult-to-treat pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF), a Phase 2 trial indicates. Bellerophon Therapeutics, which developed INOpulse, will present the trial results at an  international conference of the American Thoracic Society International Conference in Washington on May 21.
